AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01501409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium lauryl sulfate
Description: The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
Study NCT01501409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium lauryl sulfate
Description: The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
Study NCT01610960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation HELMET
Description: The HELMET and HELMET NEXT modes will be tested by each patient.
Study NCT01610960 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non invasive ventilation facemask (Respironics)
Description: The facemask Respironics (Herrsching, Germany) will be used by each patient.
Study NCT02787811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine insemenation
Description: Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
Study NCT04241809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioaerosol Sampling
Description: Cyclone collection of exhaled bioaerosol
Study NCT04418661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442720
Description: Pharmaceutical form: Varies Route of administration: Varies
Study NCT04418661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
Study NCT04418661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Pharmaceutical form:Sterile Tablet Route of administration: Oral
Study NCT01547117 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blood Volume
Description: we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
Study NCT01547117 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Blood Volume
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
Study NCT01547117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Capacity Test - Bicycle
Description: subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
Study NCT01547117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture Study
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Study NCT04815343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)
Description: Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
Study NCT02830048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Study NCT04026399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peripheral vibration stimulation
Description: wearing a wristband that delivers imperceptible vibratory stimulation.
Study NCT04026399 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: therapy
Description: practice of daily living tasks
Study NCT04026399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapy
Description: practice of daily living tasks
Study NCT02431455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometer
Description: Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
Study NCT04303468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GABA
Description: The dietary supplement GABA will be taken orally 3 times daily, before each main meal
Study NCT04303468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsule containing powdered cellulose
Study NCT01022216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera™ Wound Dressing with V.A.C.® Therapy
Description: Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
Study NCT01022216 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V.A.C.® Therapy
Description: Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
Study NCT03905681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Application of TENS pads and wearing of the TENS device.
Study NCT03905681 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Application of TENS pads and wearing of the TENS device.
Study NCT02814617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps sinensis mycelium culture extract 1.68 g
Description: Cordyceps sinensis mycelium culture extract 1.68 g
Study NCT02814617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03661216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nephure Oxalate-reducing Enzyme
Description: 3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
Study NCT03661216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
Study NCT02454868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil for intubation without neuromuscular blockade
Study NCT00999700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel - cisplatin - 5-fluorouracil
Description: docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
Study NCT00999700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.
Study NCT00999700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
Study NCT00999700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
Study NCT00999700 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.
Study NCT04274309 — intervention group
Intervention type: DEVICE
Intervention: EndoSWIR
Description: Exposition of the respected tissues to the camera
Study NCT01777737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: 24 weeks of treatment
Study NCT01777737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules to cotrimoxazole
Study NCT00743678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6/cetuximab
Description: Neoadjuvant FOLFOX6/cetuximab
Study NCT03958942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound quadratus lumborum block with bupivacaine 25%
Description: echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle
Study NCT03958942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lumbar epideural block with bupivacaine 25%
Description: lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
Study NCT03178851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
Study NCT03178851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
Study NCT03178851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
Study NCT03178851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
Study NCT00581425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imiquimod and Interferon alpha
Description: Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
Study NCT04365075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser Combined with DCB
Description: Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
Study NCT04365075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty Alone
Description: Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
Study NCT02727309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
Study NCT02313805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
Study NCT02431455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No incentive spirometer
Description: No incentive spirometer is provided to the patient, this is the study arm.
Study NCT00002796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00002796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: Given IV
Study NCT00002796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: Given orally
Study NCT00002796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma
Description: Given subcutaneously
Study NCT03871621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Medicines
Description: Anti-diabetic medications except SGLT2 inhibitors
Study NCT03871621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin tablet (10 mg)
Study NCT02168283 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: treatment arm
Description: Hypertonic peritoneal dialysis cycles
Study NCT02168283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Dietary counseling
Study NCT02168283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control arm
Description: Dietary counseling
Study NCT03139305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
Study NCT03139305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: High dose intravenous infusion for 72 hours at 25 ng/kg/min
Study NCT03139305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline for 72 hours
Study NCT01772823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3MV
Description: Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
Study NCT01772823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCC
Description: Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
Study NCT01772823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
Study NCT04640818 — intervention group
Intervention type: DRUG
Intervention: Cladribine Oral Tablet
Description: Treatment according to the label and medical prescription
Study NCT04640818 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Treatment according to the label and medical prescription
Study NCT04640818 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: Treatment according to the label and medical prescription
Study NCT04240028 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
Study NCT03100955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, etoposide
Description: The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
Study NCT03100955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide, apatinib
Description: Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
Study NCT04423172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the new tissue containment system
Description: Using the new tissue containment system during Laparoscopic hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
Study NCT02656849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1000394
Study NCT03468179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oatmeal
Description: Subjects will be fed a calculated serving of oatmeal.
Study NCT02386553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Solution for intrathecal injection
Study NCT01186731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Entrapped Docetaxel (LE-DT)
Description: 110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
Study NCT01409122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg sodium nitrite inhalation solution
Description: 15 mg sodium nitrite inhalation solution Q8H
Study NCT01409122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg sodium nitrite inhalation solution
Description: 90 mg sodium nitrite inhalation solution Q8H
Study NCT01409122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg sodium nitrite inhalation solution
Description: 45 mg sodium nitrite inhalation solution Q8H
Study NCT01409122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg sodium nitrite inhalation solution
Description: 120 mg sodium nitrite inhalation solution or placebo Q8H
Study NCT01409122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% MTD sodium nitrite inhalation solution
Description: Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
Study NCT02470923 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine replacement therapy
Study NCT02470923 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive counseling
Study NCT02470923 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medical advice
Study NCT03543605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROA Experimental
Description: PROA Control plus clinical advice
Study NCT03543605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PROA Control
Description: PROA Control
Study NCT01339624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FENTANYL
Description: FENTANYL CITRATE, NASAL, 3 GAMMA/KG
Study NCT01339624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine AND morphine
Description: morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
Study NCT03752242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-010 0.3%
Description: Safety and efficacy of BMX-010 in topical treatment of acne.
Study NCT01387815 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Adalimumab administered by subcutaneous injection.